日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶 1 (IDH1) 和 IDH2 突变型胆管癌:来自美国国家癌症研究所 10129 II 期试验的安全性和抗肿瘤活性

Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das, Biswajit; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

NCI10066:一项奥拉帕尼联合雷莫芦单抗治疗既往接受过治疗的转移性胃癌和胃食管交界处腺癌的1/2期研究

Cecchini, Michael; Cleary, James M; Shyr, Yu; Chao, Joseph; Uboha, Nataliya; Cho, May; Shields, Anthony; Pant, Shubham; Goff, Laura; Spencer, Kristen; Kim, Edward; Stein, Stacey; Kortmansky, Jeremy S; Canosa, Sandra; Sklar, Jeffrey; Swisher, Elizabeth M; Radke, Marc; Ivy, Percy; Boerner, Scott; Durecki, Diane E; Hsu, Chih-Yuan; LoRusso, Patricia; Lacy, Jill

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

奥拉帕尼治疗复发性IDH1和IDH2突变型胶质瘤的多中心II期临床试验

Fanucci, Kristina; Pilat, Mary Jo; Shyr, Derek; Shyr, Yu; Boerner, Scott; Li, Jing; Durecki, Diane; Drappatz, Jan; Puduvalli, Vinay; Lieberman, Frank Scott; Gonzalez, Javier; Giglio, Pierre; Ivy, S Percy; Bindra, Ranjit S; Omuro, Antonio; LoRusso, Patricia

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

NCI 7977:一项针对晚期实体瘤患者的间歇性口服 ABT-888(维利帕尼)联合静脉注射伊立替康的 I 期剂量递增研究

Cecchini, Michael; Walther, Zenta; Wei, Wei; Hafez, Navid; Pilat, Mary Jo; Boerner, Scott A; Durecki, Diane E; Eder, Joseph P; Schalper, Kurt A; Chen, Alice P; LoRusso, Patricia

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

确定BRAFV600野生型转移性黑色素瘤的治疗方案:一项基于SU2C/MRA基因组学的临床试验

LoRusso, Patricia M; Sekulic, Aleksandar; Sosman, Jeffrey A; Liang, Winnie S; Carpten, John; Craig, David W; Solit, David B; Bryce, Alan H; Kiefer, Jeffrey A; Aldrich, Jessica; Nasser, Sara; Halperin, Rebecca; Byron, Sara A; Pilat, Mary Jo; Boerner, Scott A; Durecki, Diane; Hendricks, William P D; Enriquez, Daniel; Izatt, Tyler; Keats, Jonathan; Legendre, Christophe; Markovic, Svetomir N; Weise, Amy; Naveed, Fatima; Schmidt, Jessica; Basu, Gargi D; Sekar, Shobana; Adkins, Jonathan; Tassone, Erica; Sivaprakasam, Karthigayini; Zismann, Victoria; Calvert, Valerie S; Petricoin, Emanuel F; Fecher, Leslie Anne; Lao, Christopher; Eder, J Paul; Vogelzang, Nicholas J; Perlmutter, Jane; Gorman, Mark; Manica, Barbara; Fox, Lisa; Schork, Nicholas; Zelterman, Daniel; DeVeaux, Michelle; Joseph, Richard W; Cowey, C Lance; Trent, Jeffrey M

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma

卡非佐米、来那度胺和低剂量地塞米松治疗老年新诊断多发性骨髓瘤患者

Dytfeld, Dominik; Jasielec, Jagoda; Griffith, Kent A; Lebovic, Daniel; Vesole, David H; Jagannath, Sundar; Al-Zoubi, Ammar; Anderson, Tara; Detweiler-Short, Kristen; Stockerl-Goldstein, Keith; Ahmed, Asra; Jobkar, Terri; Durecki, Diane E; McDonnell, Kathryn; Mietzel, Melissa; Couriel, Daniel; Kaminski, Mark; Vij, Ravi; Jakubowiak, Andrzej J